Drugs / diphtheria, tetanus, and acellular pertussis vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01200368 | Sep 2010 → Nov 2011 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | diphtheria, tetanus, and acellular pertussis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01200368 ↗ |
| Known as | DTaP | “Healthy Japanese infants received PCV13 and diphtheria, tetanus and acellular pertussis vaccine (DTaP), PCV7 and DTaP or DTaP alone subcutaneously” PMID 26121200 ↗ Oct 2015 |
| Modality | Vaccine | “diphtheria, tetanus, and acellular pertussis vaccine (DTaP)” NCT01200368 ↗ |
| Route | Subcutaneous | “Healthy Japanese infants received PCV13 and diphtheria, tetanus and acellular pertussis vaccine (DTaP), PCV7 and DTaP or DTaP alone subcutaneously” PMID 26121200 ↗ Oct 2015 |